| 000 | 01396 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517015938.0 | ||
| 264 | 0 | _c20160712 | |
| 008 | 201607s 0 0 eng d | ||
| 022 | _a1179-1918 | ||
| 024 | 7 |
_a10.1007/s40261-015-0272-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Jianhua | |
| 245 | 0 | 0 |
_aIncidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies. _h[electronic resource] |
| 260 |
_bClinical drug investigation _cApr 2015 |
||
| 300 |
_a221-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xchemically induced |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xcomplications |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aYoung Adult |
| 650 | 0 | 4 | _aRamucirumab |
| 700 | 1 | _aWang, Zexing | |
| 700 | 1 | _aZhao, Yunzhao | |
| 773 | 0 |
_tClinical drug investigation _gvol. 35 _gno. 4 _gp. 221-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40261-015-0272-z _zAvailable from publisher's website |
| 999 |
_c24638886 _d24638886 |
||